Press release summary
Researchers used Alamar Biosciencesโ NULISAqpcr platform to measure a plasma tau fragment associated with advanced chronic traumatic encephalopathy pathology in a study published in JAMA.
The research examined eMTBR-tau in former football players whose CTE status had been established through postmortem neuropathology. Higher blood concentrations were reported in people with high-stage CTE than in those with low-stage or no CTE, and concentrations increased with the measured burden of tau tangles in brain tissue.
The team also measured p-tau217, a biomarker associated with Alzheimerโs disease. According to the announcement, p-tau217 tracked Alzheimer pathology but was not associated with CTE, suggesting the two measurements could help researchers distinguish overlapping disease processes.
The authors described the findings as early and requiring validation in larger, more diverse cohorts. The eMTBR-tau test is not available for clinical use, and no blood test has been validated to diagnose CTE in living patients.
Why it matters to laboratory readers
The work illustrates how ultrasensitive protein measurement can support biomarker discovery when analytes are present at low concentrations and clinical reference standards are limited. Laboratories interpreting similar studies should examine specimen quality, assay precision, calibration, analytical specificity, preanalytical variables and the difference between association with pathology and validated diagnostic performance.
Original source: Alamar Biosciences, Nov. 20, 2026.







Leave a Reply